Communiqués SynAct Pharma AB

Actions

SYNACT

SE0008241491

Produits pharmaceutiques

PEA

Temps Différé Nasdaq Stockholm 12:05:05 31/08/2026			Varia. 5j.	Varia. 1 janv.
19,62 ^SEK	-1,51 %		+3,26 %	-13,19 %

28/08	Synact Pharma présente de nouvelles données précliniques pour le resomelagon au WCI	FW
20/08	SynAct Pharma AB publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

28/08	SynAct Pharma to present new resomelagon preclinical data on Phase 3-ready RA therapeutic candidate at the 17th World Congress of Inflammation 2026	AQ
20/08	SynAct Pharma (Q2 Review): Fenja Financing Backs the Post-ADVANCE Push	AQ
20/08	SynAct Pharma publishes Q2 2026 interim results	AQ
19/08	SynAct Pharma: Term Sheet Signed for Brazil	AQ
19/08	SynAct Pharma progresses first commercial agreement on resomelagon for treatment of dengue in Brazil – term sheet signed	AQ
05/08	SynAct Pharma receives favorable US patent decision for immediate-release resomelagon tablet formulation	AQ
20/07	SynAct comments on the SEK 100 million facility	AQ
20/07	SynAct Pharma strengthens financial position and strategic flexibility to advance partnering discussions and Phase III readiness	AQ
09/07	Resomelagon shows reduced inflammation and joint damage in osteoarthritis model	AQ
02/07	SynAct Pharma : Company presentation	PU
02/07	SynAct Pharma : Bolagspresentation	PU
29/06	BIO International USA confirms growing interest in resomelagon and SynAct Pharma following the positive effects of the ADVANCE study	AQ
16/06	SynAct Pharma: Updated Base Case after ADVANCE	AQ
15/06	SynAct Pharma (Interview): ADVANCE Topline Data	AQ
15/06	SynAct Pharma: 40mg Best Dose in ADVANCE	AQ
15/06	SynAct Pharma Board of Directors and Management Enter Lock-up Agreements	AQ
15/06	SynAct Pharma : Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis - supports phase 3 design, regulatory interactions, and partnering	PU
15/06	Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis – supports phase 3 design, regulatory interactions, and partnering	AQ
12/06	SynAct obtains key US patent for resomelagon securing exclusivity until 2044	AQ
11/06	Report from the 2026 Annual General Meeting of SynAct Pharma AB (publ)	AQ
27/05	SynAct Pharma publishes Q1 2026 interim results	AQ
26/05	Synact Pharma large shareholder trading update	AQ
19/05	SynAct Pharma to present at the BioStock Global Forum 2026 on May 21	AQ
07/05	Notice of annual general meeting in SynAct Pharma AB	AQ
06/05	SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout	AQ